DOI 10.1016/j.ijantimicag.2026.107825
Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial.
Аннотация
OBJECTIVE
To evaluate if switching from dolutegravir/lamivudine (DTG/3TC) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) improves neuropsychiatric tolerability in suppressed adults with stable neuropsychiatric comorbidities.
METHODS
MIND was a phase IV, randomised, double-blind, multicentre trial. Participants were assigned (1:1) to switch to BIC/FTC/TAF or continue DTG/3TC. The primary endpoint was the proportion of grade 2-4 neuropsychiatric adverse events (NP-AEs) at week 24. Secondary endpoints included safety, virological maintenance, and patient-reported outcomes (PROs) through week 48.
RESULTS
Eighty participants were randomised (BIC/FTC/TAF, n = 41; DTG/3TC, n = 39). At week 24, grade 2-4 NP-AEs occurred in 14.6% of the BIC/FTC/TAF arm vs 17.9% in the DTG/3TC group (difference: 3.3% [95%CI -19.5 to 12.9]; P = 0.688). At week 48, incidences were 21.9% vs 17.9% (difference: 4.0% [95%CI -13.5 to 21.5]; P = 0.650). NP-AE-related discontinuations were low (7.3% vs 5.1%). At week 24, BIC/FTC/TAF showed less moderate-to-severe nausea/vomiting (3.8% vs 23.2%; P = 0.027) and abdominal discomfort (16.8% vs 40.2%; P = 0.04). At week 48, BIC/FTC/TAF reported more headache (55.7% vs 26.1%; P = 0.03) but fewer skin symptoms (24.9% vs 49.2%; P = 0.022). All maintained virological suppression at week 48; four participants on DTG/3TC met failure criteria but achieved re-suppression without emergent resistance. PRO trajectories and treatment satisfaction remained high and stable throughout the study, with no significant between-group differences.
CONCLUSIONS
In PLWH with stable neuropsychiatric comorbidities, switching to BIC/FTC/TAF did not reduce NP-AEs or improve PROs versus continuing DTG/3TC. Both regimens were safe and highly effective at maintaining virological suppression through 48 weeks.
TRAIL NUMBER: NoEUDRACT:2021-005927-19.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.